Loading...
•
Dec 31, 2022
Wave Life Sciences Q4 2022 Earnings Report
Wave Life Sciences reported financial results for Q4 2022 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $43.7 million in the fourth quarter of 2022. They entered into a strategic collaboration with GSK and are advancing their RNA editing and other platform capabilities.
Achieved clinical validation of PRISM platform in 2022.
Extended leadership in RNA editing and advanced WVE-006 for AATD.
Initiating Part B of WVE-N531 study in exon 53-amenable DMD.
Strategic collaboration with GSK underway.
Forward Guidance
Wave anticipates several milestones in the near future.
Positive Outlook
- Initiate dosing in Part B of WVE-N531 clinical trial in 2023
- Deliver data from Part B in 2024
- Submit CTAs for first-in-human study in 2H 2023
- Deliver additional single-dose biomarker and safety clinical data in 1H 2023
- Deliver additional single- and multi-dose biomarker and safety clinical data in 1H 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...